enoxaparin + warfarin + apixaban

This therapeutic entry refers to a clinical trial protocol or treatment strategy involving three distinct anticoagulants—enoxaparin, warfarin, and apixaban—evaluated for the management of portal vein thrombosis (PVT) in patients with liver cirrhosis. Enoxaparin is a low-molecular-weight heparin (LMWH) that acts by binding to and accelerating the activity of antithrombin III, thereby inhibiting Factor Xa and thrombin. Warfarin is a vitamin K antagonist that interferes with the hepatic synthesis of vitamin K-dependent coagulation factors (II, VII, IX, and X). Apixaban is a direct oral anticoagulant (DOAC) that serves as a selective, reversible inhibitor of Factor Xa. The specific context for this combination is a Phase 4 clinical trial conducted by Mansoura University to assess the efficacy and safety of these agents in cirrhotic patients, including those with hepatocellular carcinoma (HCC).

Other names

Enoxaparin, warfarrin, or apixaban